Moderna Beats Revenue Expectations on Strong International COVID Vaccine Sales

The news indicates that Moderna has exceeded revenue expectations, driven by robust international COVID vaccine sales. This positive development could support the stock price in the short term. Technical indicators also confirm the upward trend: the RSI is at 63, in neutral territory but with an upward bias; the MACD is above its signal line; and the price is above both the 20-day and 50-day moving averages. The 9.3% increase over the past 24 hours suggests strong momentum. Since the stock is not yet in overbought territory, the likelihood of continued short-term upside is high.

GOOGL stock is exhibiting a strong uptrend, with the RSI approaching the overbought zone at 71.4. The MACD remains above the signal line and in positive territory, indicating sustained short-term momentum. The price is trading well above the 20-day and 50-day moving averages, confirming the bullish trend. However, since the news headline pertains to Moderna, the direct impact on GOOGL may be limited. In the short term, upside potential could persist, but the overbought zone presents some risk of profit-taking.